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ABSTRACT
Even when treated adequately, pulmonary tuberculosis can lead to pulmonary sequelae. 
Patients treated for PTB between 2012 and 2016 answered a standardized questionnaire and 
underwent chest radiography and spirometry, measurement of absolute pulmonary volume, 
Diffusing Capacity for Carbon Monoxide (DLCO) and the 6-min walk test (6MWT) on two 
occasions: within the first year after the end of treatment (follow-up 1), and one and two 
years after follow-up 1 (follow-up 2). A total of 55 patients they underwent spirometry, 23 
(41.82%) had obstructive ventilatory disorder (OVD) and eight (14.5%) had moderate OVD. 
In total, 29 patients underwent pulmonary function tests (PFTs) and 24 patients underwent 
the 6MWT on two occasions. The functional changes after PTB treatment appear not to 
have varied between one and two years of follow-up. There was a correlation between low 
FEV
1
 and low DLCO (p<0.001); low DLCO and low 6MWT (p<0.001) and radiographic 
abnormalities and low FEV
1
 (p=0.033). The most frequently observed change in spirometry 
was found in patients with OVD. 
KEYWORDS: Spirometry. 6-minute walk test. Lung capacity. Tuberculosis sequelae.
INTRODUCTION
Tuberculosis (TB) is a global public health problem and its control has been a 
challenge in recent decades. In 2019, the incidence of the disease ranged from 8.9 to 
11.1 million new cases of active TB and between 1.1-1.3 million deaths due to TB 
according to the World Health Organization (WHO), indicating that TB is currently 
the leading cause of death from infectious causes worldwide and is among the top 
10 causes of death in general1.
Even when treated adequately, pulmonary TB (PTB) can lead to pulmonary 
sequelae. Reduction in the total lung capacity (TLC) due to scar fibrosis is common2. 
In addition, destructive changes in the pulmonary parenchyma can lead to airflow 
obstruction3. These changes might affect the pulmonary compliance, resulting in 
peripheral airway collapse and, consequently, air trapping, leading to changes in 
pulmonary function2.
Radiological sequelae of PTB might be related to dynamic changes in 
pulmonary function after the end of treatment2. According to a longitudinal study by 
Chung et al.4, deterioration in the pulmonary function might occur up to 18 months 
after the end of treatment. 
Functional changes resulting from the sequelae might manifest as ventilatory 
restriction, ventilatory obstruction or a combined disorder (obstructive–restrictive 
together)5.
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In a systematic review, after the evaluation of 156 
articles, obstruction was mentioned in 52 (33%)6, and 
even in countries with low incidences of PTB, respiratory 
diseases are frequent after treatment of PTB7. The 
proportion of obstruction is variable and was related to the 
extent of radiological changes8,9. On the other hand, the 
restriction has been the most frequent disorder in recently 
published studies, observed in 52 to 68%10-12. A multicentric 
study in Brazil, that evaluated the functional changes in 
patients treated for PTBafter excluding smoking patients 
and those with respiratory diseases prior to PTB treatment, 
the restriction has also been the predominant change9.
The 6-minute walk test (6MWT), used to evaluate an 
individual’s response to exercise, is reliable and has been 
validated according to the guidelines of the American 
Thoracic Society13. Some studies have reported patients 
with PTB who walked shorter distances during the 6MWT 
in comparison with healthy individuals; this was seen 
even in patients during treatment or who had successfully 
completed the treatment regimen14-16. In recent years, a 
difference in the 6MWT distance has been noted after 
the end of treatment in patients with TB and human 
immunodeficiency virus (HIV) infection17.
Another test to assess the pulmonary function is the 
diffusing capacity of carbon monoxide (DLCO)18. Patients 
with PTB might have low DLCO and only a few studies 
evaluated the specific relationship between DLCO and 
PTB2,8. The mean DLCO varied from 74.1% to 78.8% in 
patients with TB sequelae, highlighting the importance of 
evaluating this parameter to assess pulmonary function2,18.
A recent review found an abundance of studies on 
the prevalence and proportion of post PTB disorders. On 
the other hand, there was a lack of studies on the disease 
progression and patients’ management6. There was 
consensus on the need for follow-up after PTB treatment 
as some evidences have emerged pointing to an increased 
risk of morbidity and mortality in the post PTB period19. 
Thus, this study aimed to evaluate the magnitude and 
progression of respiratory changes in spirometry according 
to the variables: absolute pulmonary volume, DLCO and 
6MWT in patients treated for PTB.
MATERIALS AND METHODS
This prospective study included new cases of TB 
confirmed by smear microscopy or GeneXpert®MTB/RIF 
(Cepheid, Sunnyvale, CA, USA) and positive culture for 
M. tuberculosis in patients who sought the Tuberculosis 
Outpatient Clinic of the Clinical Hospital of the Federal 
University of Minas Gerais, who were successfully treated 
for PTB from January 1st, 2012 to December 30th, 2016. 
All patients signed an informed consent and received 
multiple treatments for PTB. Patients presenting with 
extrapulmonary TB, coinfected with the human the 
immunodeficiency virus (HIV) or presenting with 
unacceptable or non-reproducible spirometry curves were 
excluded.
Recruited patients answered a standardized questionnaire 
comprising questions on sociodemographic and clinical 
data, gender, age (≥ 18 years), history of smoking habit 
and comorbidities. Some of these patients participated in a 
previous study by the same authors9. The sociodemographic 
variables were self-declared skin color/ethnicity (white 
or non-white) and marital status (single or stable union). 
Regarding respiratory signs and symptoms, the presence 
of dyspnea, classified according to the modified Medical 
Research Council (mMRC) scale20, cough, sputum and 
wheezing was evaluated. These data were obtained on 
the day the pulmonary function tests (PFTs) were carried 
out. Individuals who smoked at least 100 cigarettes or the 
equivalent during their lifetimes were considered smokers, 
and individuals who had quit smoking for >12 months 
prior to study inclusion were considered ex-smokers21. 
Comorbidities were self-reported and valued when 
described in the medical records. Diagnosis of lung diseases 
(asthma, chronic obstructive pulmonary disease [COPD], 
bronchiectasis, interstitial lung disease and silicosis) prior 
to PTB treatment was reviewed by pulmonologists involved 
in this study, according to the definitions proposed by 
international guidelines such as the Global Initiative for 
Asthma, the Global Initiative for Obstructive Chronic Lung 
Disease and Pulmonology Practice22-24.
PFTs were performed in the first follow-up within 
the first year after the end of treatment (follow-up 1) and 
repeated between one and two years after the follow-
up 1 (follow-up 2). The Collins CPL system (Ferraris 
Respiratory, Louisville, CO, USA) was used to perform the 
tests. The acceptance and reproducibility criteria for PFTs 
were set according to the recommendations of the American 
Thoracic Society (ATS)25. Data were reported as absolute 
values and percentages in relation to the predicted values 
for the Brazilian population26. The following variables 
were analyzed: total lung capacity (TLC), residual volume 
(RV), RV/TLC ratio, forced vital capacity (FVC), forced 





ratio27. DLCO was performed using the single-breath 
method, and the values suggested by Crapo and Morris28 
were used. 
OVD was considered when the FEV
1
/FVC ratio was 
below the lowest limit of normal (LLN) and TLC was 
≥  LLN; combined ventilatory disorder (obstructive–
restrictive together) was considered when the FEV
1
/FVC 
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ratio was below the LLN and TLC was < LLN; RVD was 
considered when the FEV
1
/FVC ratio was above or equal to 
the LLN and TLC was < LLN; and the non-specific pattern 
(IVD) was considered when the FVC value was below the 
LLN, the FEV1/FVC ratio was equal to or above the LLN, 
and TLC was ≥ LLN.27 To classify the severity of obstruction 





was used, with ≥ 60% corresponding to mild, 41-59% to 
moderate, and ≤ 40% to severe obstruction; to predict the 
percentage of prediction, FVC ≥ 60% corresponded to mild, 
51-59% to moderate, and ≤ 50% to severe restriction29.
The 6MWT was performed in a 30-m corridor using a 
portable oximeter (Nonin Medical, INC. Plymouth, MN, 
USA) according to the recommendations of the ATS30. All 
patients underwent two walking tests, with a minimum 
interval of 30 minutes; encouraging phrases were provided 
every minute. The following parameters were recorded: 
heart rate, respiratory rate and dyspnea score (Borg score 
of dyspnea); saturation was measured by pulse oximetry 
(SpO2) at the beginning and at the end of the test; and the 
walking distance at the end of the 6MWT30. The test with 
the greatest distance covered in the 6MWT was selected. 
The 6MWTD findings were expressed as absolute values 
and percentages of the predicted values calculated using 
the reference equation proposed by Soares and Pereira31 
for the Brazilian population. 
Chest X-rays were performed on days close to the 
spirometry, they were evaluated by radiologists and 
classified by pulmonologists. Chest X-rays that showed 
no abnormalities were classified as normal. Chest X-rays 
that showed abnormalities were classified according to the 
National Tuberculosis Association (NTA), as follows: NTA 
I or minimum; NTA II or moderately advanced - the injury 
could be in one lung or in both lungs, its extension should 
not exceed the volume corresponding to an entire lung if the 
lesions are not confluent, and in the presence of confluent 
lesions, they should occupy no more than the equivalent of 
one-third of the lung; NTA III or very advanced -exceeding 
the moderately advanced limit32.
The sample calculation considered a 95% confidence 
interval and a margin of error < 5%, including the average 
number of patients diagnosed with PTB evaluated per 
year at the Tuberculosis Outpatient Clinic of the Clinical 
Hospital of UFMG and the percentage of patients who 
developed pulmonary sequelae. The estimated minimum 
sample size resulted in 32 patients.
Data were collected using an Excel spreadsheet 
and analyzed using the Statistical Package software for 
the Social Sciences, version 24.0 (SPSS Inc, Chicago, 
IL, USA). The Kolmogorov–Smirnov test was used to 
assess the normality of continuous numerical variables 
distribution. C variables are expressed as means and 
standard deviations or as medians and interquartile intervals, 
while categorical variables are expressed as absolute and 
relative frequencies. The chi-square test was used for 
the comparison of categorical variables. To analyze the 
variables of lung function tests between follow-ups 1 and 
2, the unpaired Student’s test or the Mann–Whitney test 
was performed, as indicated. To verify the direction and 
the degree of association between pulmonary function 
variables, either Pearson or Spearman’s coefficient was 
performed; as indicated. We set the significance level at 
5% (p < 0.05).
This study is part of a project approved by the Research 
Ethics Committee of the Federal University of Minas Gerais 
(CAAE Nº 14606113.7.0000.5149).
RESULTS
From the 57 selected patients, 55 were included in 
the analyses and two were excluded because they did not 
meet all inclusion criteria (Figure 1). Table 1 shows the 
main characteristics of the participants. The mean age was 
50.4 years (22.2–77.1 years), 52.7% (29/55) were female, 
43.6% (24/55) were non-white and 52.7% (29/55) patients 
had a stable union. Some comorbidities were observed in 
60% (33/55) of patients, and systemic arterial hypertension 
Figure 1 - Flowchart of the participants’ eligibility and their 
inclusion in the study. *2 patients did not meet all inclusion 
criteria of spirometry; **19 participants did not have pulmonary 
volume measurements and DLco in follow-up 1 due to technical 
problems with the equipment; #9 Participants did not have 6MWT 
in follow-up 1; 2 for disability due rheumatoid arthritis and 7 
for absence on the day of the exam; ***7 participants did not 
have PFTs during follow-up 2 due to technical problems with 
the equipment; ##22 participants did not have 6MWT during 
follow-up 2, 15 due to lack of medical request for the exam and 
7 for absence on the day of the exam.
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was observed in 41.82% (23/55) of patients. Respiratory 
symptoms were reported by 81.8% (45/55) of patients, 
and 78.2% (43/55) reported dyspnea (Table 1). In total, 
54.5% (30/55) of patients were smokers or ex-smokers. The 
smoking load was 33.9 packs-year, with a minimum of 2 
packs-year and a maximum of 174 packs-year. Furthermore, 
61.8% (34/55) of patients had minimal abnormalities on 
their chest X-ray (Table 1). Considering the 55 patients who 
underwent at least one examination with acceptable and 
reproducible spirometry curves, 36 patients underwent tests 
for absolute pulmonary volume and DLCO and 46 patients 
underwent the 6MWT (Figure 1). The absolute values and 
percentages of the predicted values obtained in the PFTs are 
shown in Table 2. The most prevalent ventilatory disorder 
was OVD; it was observed in 23/55 (41.82%) patients; 8/55 
(14.5%) patients had moderate OVD (Table 3).
From the 55 selected patients, 29 underwent pulmonary 
volume and DLCO tests, and 24 patients underwent the 
6MWT on two occasions (Table 4). The median duration 
between the end of treatment and follow up 1 was 147 days 
(range, 75-363), and between follow-up 1 and follow-up 2 
was 634 days (range, 458-1127). When the results of PFTs 
and 6MWTD variables were compared in the two follow-
ups, no statistical difference was observed between the 
Table 1 - Sociodemographic and clinical characteristics of the sample (n=55). 
Characteristics n (55) %
Gender Male 26 47.3
Female 29 52.7
Age group (in years) Up to 29 5 9.1
30-49 20 36.3
50-59 13 23.6
> 60 17 30.9
Self-declared skin Color/Ethnicity White 19 34.5
Not White 36 65.5
Marital status Single 26 47.3
Not single (stable relationship) 29 52.7





RA or SS 3 5.4
Granulomatous polyangiitis 1 1.8
COPD 7 12.7
Signs/Symptoms Cough 19 34.5
Wheezing 12 21.8
Dyspnea mMRC 0-1 32 58.2
mMRC 2 – 4 23 41.8
Smoking No 25 45.5
Former smoker 11 20.0
Yes 19 34.5
Chest X-ray Normal 9 16.4
NTA I 34 61.8
NTA II 7 12.7
NTA III 1 1.8
Not informed 4 7.3
SAH = systemic arterial hypertension; DM = diabetes mellitus; CKD = chronic kidney disease; RA = rheumatoid arthritis; SS = systemic 
sclerosis; COPD = chronic obstructive pulmonary disease; NTA = National Tuberculosis Association; mMRC = modified Medical 
Research Council.
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evaluated parameters (Tables 4 and 5, and Supplementary 
Figure S1).
Analyses of chest X-ray abnormalities and FEV1 
values revealed that patients with X-ray changes had lower 
FEV1 values (p=0.033), (Supplementary Figure S2). A 
significant correlation was observed between FEV1 and 
DLCO (R=0.564; p<0.001), (Supplementary Figure S3), 
and between FEV1 and 6MWTD (R=0.506, p<0.001), 
(Supplementary Figure S4); between DLCO and 6MWTD 
(R=0.592, p<0,001), (Supplementary Figure S5). Thus, 
patients with lower FEV1 and lower DLCO had a worse 
performance in the 6MWT, i.e. walked shorter distances.
There was no significant correlation between chest 
X-ray abnormalities and DLCO (p=0.246), presence 
of symptoms and DLCO (p=0.163), FEV1 and DLCO 
(p=0.384) and 6MWTD and DLCO (p=0.357).
DISCUSSION
The main study results showed that the functional 
changes after PTB treatment seem not to vary between one 
and two years follow-up.
We did not find significant differences in pulmonary 
function of patients 12 and 24 months after PTB treatment. 
Allwood et al.2 showed that during treatment, lung 
volumes improved and computed tomography fibrosis 
scores decreased, but features of airflow obstruction and 
gas trapping emerged, while reduced DLCO seen in a 
majority of patients persisted. Furthermore, one year 
after the end of treatment, 18.6% of patients had residual 
restriction disorders, 16.3% had airflow obstruction, and 
78.6% had reduced DLCO. Chung et al.4 found lower 
spirometry values 18 months after treatment; however, their 
study included patients in treatment for non-tuberculosis 
mycobacteria (NTM). Hnizdo et al.33 reported decreased 
values approximately 6 months after treatment, with 
stabilization of the changes between 7-12 months; despite 
the fact that their sample was composed of coal miners 
and included patients with more than one episode of PTB. 
A strength of our study, in comparison with authors who 
Table 2 - Basal variables (follow-up 1) of pulmonary function 




FVC, L 3.25 (0.94)
FVC, % 87.79 (18.02)
FEV1, L 2.37 (0.69)
FEV1
 , % 78.39 (17.46)
FEF25-75, L/S 2.11(1.01)
FEF25-75, % 72.65 (35.28)




TLC, L 5.27 (1.37)
TLC, % 101.21 (18.78)
VR,L 1.81 (0.80)
VR, % 100.96 (34.12)
RV/TLC, % 33.97 (9.87)
DCO (n=36)
DCO, mL min-1 mmHg-1 25.46 (8.36)
DCO, % 86.48 (23.59)
6MWTD (n=46)
6MWTD, m 526.07 (95.07)
6MWTD, % 90.31 (14.58)
SD = standard deviation; L = liters; % = predicted percentage; 
m = meters; VC = vital capacity; FVC = forced vital capacity; 
FEV1 = forced expiratory volume in 1 s; FEF25-75 = forced 
expiratory flow between 25 and 75% of the forced vital capacity; 
TLC = total lung capacity; VR = residual volume; DCO = diffusing 
capacity for carbon monoxide; 6MWTD = 6-min walk test 
distance; 6MWTD% = 6-min walk test distance. 
Table 3 - Functional classification of ventilator disorders detected during the follow-up of patients treated for pulmonary tuberculosis 
(n=55).











NVD 1 1.83 - 1 1.81
Total 55 100.0 - - -
OVD = Obstructive Ventilatory Disorder; RVD = Restrictive Ventilatory Disorder; DVC = Mixed Ventilatory Disorder; NVD = Nonspecific 
Ventilatory Disorder.
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have also evaluated lung function longitudinally, was to 
include patients who performed lung function after the 
end of treatment, thus reducing the interference of changes 
in lung function during the acute phase of PTB infection. 
In addition, as shown by Allwood et al.2, between 6 and 
18 months after the diagnosis of PTB, tomography changes 
are more stable. Ravimohan et al.3 described the complexity 
of possible immunological and inflammatory pathways that 
can result in destruction of the lung tissue, consequently 
leading to changes in long term changes in lung function. 
The most prevalent ventilatory disorder found in our 
study was of mild OVD, which is consistent with findings 
reported in most studies7,34,35. The pathophysiological 
mechanism that leads to obstructive functional changes 
after PTB is not well established. One possibility would 
be the occurrence of bronchiectasis and bronchial stenosis. 
Another explanation is that they are caused by dysregulation 
of macrophage activity, leading to an initial destruction of 
Table 4 - A comparison of pulmonary function tests results between follow-ups 1 and 2 (n=29). 







VC, L 3.3 (1.0) 3.1 (0.9) 0.983
VC, % 84.3 (19.6) 83.4 (20.1) 0.396
FVC, L 3.1 (1.0) 3.1 (0.9) 0.767
FVC, % 75.2 (27.8) 81.1 (17.4) 0.258
FEV1 2.1 (0.9) 2.2 (0.9) 0.666
FEV1
 , % 58.7 (29.8) 69.0 (23.4) 0.330
FEF25-75%, L 1.6 (1.2) 1.9 (1.4) 0.360
FEF25-75%, % 64.02 (36.06) 62.78 (42.95) 0.556
FEV1/ FVC 70.64 (14.53) 68.53 (19.83) 0.458
Absolute Pulmonary 
Volume 
TLC 5.7 (1.4) 4.9 (1.1) 0.878
TLC, % 102.3 (21.7) 93.1(16.2) 0.878
VR,L 2.1 (1.1) 1.8 (1.8) 0.919
VR, % 112.1(40.3) 101.8 (24.5) 0.646
FRC, L 3.2 (1.1) 2.8 (0.8) 0.444
FRC,% 100.7 (26.9) 91.1 (19.4) 0.799
RV/TLC 38.6 (12) 37.6 (10.1) 0.889
DLCO DLCO, mL min-1 mmHg-1 25.1 (9.2) 22.8 (9.78) 0.310
DLCO, % 82.1 (26.1) 75.4(21.7) 0.398
SD = Standard Deviation; L = liters; % = predicted pergentage. ; RV = Residual Volume; FRC = Functional Residual Capacity; 
TLC = Total Lung Capacity; VC = Vital Capacity; FVC = Forced Vital Capacity; FEV1 = Forced Expiratory Volume in 1s; FEF25-75 = Forced 
Expiratory Flow Between 25 and 75% of the CVF; DLCO = Diffusing Capacity for Carbon Monoxide. 







SpO2 initial (%) 96.21(1.46) 95.81 (1.60) 0.652
SpO2 final (%) 93.03 (4.35) 90.44 (5.96) 0.681
HR initial (bpm) 80.53 (16.73) 80.38 (14.07) 0.103
HR final (bpm) 115.95 (16.62) 122.88 (14.96) 0.948
RR initial (brpm) 18.0 (3.04) 17.25 (3.49) 0.222
RR final (brpm) 26.49 (4.86) 24.73 (3.31) 0.254
6MWTD, m 498.3 m (114.4) 494.0 (94.4) 0.999
6MWTD, % 85.7 (21.2) 86.7 (18.2) 0.470
SD = standard deviation; SpO2 = saturation by pulse oximetry; HR = heart rate; RR = respiratory rate; brpm = breaths per minute; 
6MWTD = 6-min walk test distance; bpm = beats per minute; 6MWTD % = 6-min walk test distance in predicted percentage.
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pathogenic microorganisms, favoring tissue healing and 
playing a central role in tissue remodeling3. Restrictive 
disorders could be due to destruction of pulmonary 
parenchyma by the deregulation of the mechanism of 
protease control, i.e., pulmonary damage caused by matrix 
metalloproteinases leading to fibrotic changes3. Around 
50% of restrictions take place one year after the PTB 
treatment10,11.
Among patients who reported respiratory symptoms, 
dyspnea was the most frequent symptom, although it was 
not correlated with pulmonary function changes, since most 
patients had mild dyspnea (mMRC scale score: 0-1), similar 
to a previous study36. Another study described self-reported 
symptoms, airflow obstruction and functional impairment 
1-5 years after TB treatment with poor correlation between 
physiology, functional capacity and symptoms, although it 
was also a cross-sectional study34.
Most patients did not show radiological abnormalities 
or had minimal lesions. However, patients with radiological 
changes had lower FEV
1
. Allwood et al.2 showed that these 
changes may be secondary to the trapping of physiological 
gases, suggesting the development of airflow limitation at 
the level of the small airways. 
A good correlation between FEV1 and DLCO with 
6MWTD is an interesting and new finding in our study; 
when FEV1and DLCO was lower in patients who walked 
shorter distances as shown by the 6MWT, suggesting 
worsening of gas exchange and greater severity of the 
disease in these patients18. However, the equipment 
that measures DLCO is not widely available in most 
underdeveloped or developing countries, exactly in places 
in which the prevalence of post-PTB treatment changes is 
more significant6.
In our study, patients walked distances close to 
the predicted value in two different times and without 
significant difference, which might demonstrate the 
stability of functional capacity. A South Africa cohort 
demonstrated similar 6MWTD results with respect to 
ours despite including patients that underwent up to six 
treatments for TB34. In a previous study with only nine 
participants, five of the nine showed values below LLN after 
PTB treatment37. Our results can be justified by the Latin 
American population included in this study, which are used 
to walk longer distances than Nordic populations, probably 
due to lifestyle habits38.This study has some limitations. 
Firstly, this was a single-center trial; hence, the results 
cannot be generalized, however, to our knowledge, there are 
few studies that evaluated lung function at different periods 
after the end of TB treatment in the same patients. Secondly, 
this study included patients with COPD and smokers, which 
might have interfered with the results. Nevertheless, the 
high prevalence of smoking among these patients reflects 
the real-life clinical practice. People who are at higher risk 
to contract TB are often the same ones exposed to other risk 
factors for chronic respiratory diseases, including exposure 
to household smoke, ambient air pollution and occupational 
exposure to dust6.
CONCLUSION
In the present study, 55 treated TB patients were 
evaluated. They underwent spirometry, 23 (41.82%) had 
obstructive respiratory disorders (OVD) and eight (14.5%) 
s had moderate OVD. Twenty-nine patients underwent 
pulmonary function tests (PFTs) and 24 the 6MWT on two 
occasions. Functional changes after PTB treatment appear 
not to have varied between one and two years of follow-up. 
There was correlation between low FEV
1
 and low DLCO 
(p<0.001); low DLCO and low 6MWT distance (p<0.001) 
and X-ray abnormalities and low FEV
1
 (p=0.033). The 
most frequently observed change in spirometry was found 
in patients with OVD. 
Functional changes appear not to vary between one and 
two years after PTB treatment. The end of PTB treatment 
may represent the starting point of another disease with 
permanent changes in lung function. The importance of 
performing PFTs should be emphasized, especially in 
patients who have radiological sequelae.
Further studies should be conducted to identify and 
evaluate pulmonary changes that are clinically relevant and 
measures that can help patients with respiratory symptoms 
after PTB treatment, such as the use of inhaled drugs 
and pulmonary rehabilitation. Moreover, we emphasize 
the importance of PTB prevention since sequelae are 
irreversible despite adequate treatment, leading to clinical 
and economic losses that the patients would have to bear 
throughout their lives.
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Supplementary Figure S1 – Change of lung function variables 
between the follow-up 1 and 2. a) FVC in liters and %; b) FEV1 
in liters and % c) 6MWTD in meters and %; FVC = forced 
vital capacity; FEV1 = forced expiratory volume in 1 second; 
6MWTD = 6-min walk test distance; L = liters, % = predicted 
percentual.
SUPPLEMENTARY MATERIAL
Supplementary Figure S2 - Analysis between FEV1 (liters) 
and Chest X-ray, during follow-up 1.
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Supplementary Figure  S3 - Correlation between FEV1 
(liters) and DLCO (mL  min-1  mmHg-1) during follow-up  1. 
DLCO = diffusing capacity for carbon monoxide; FEV1 = forced 
expiratory volume in 1 second. 
Supplementary Figure S4 - Correlation between FEV1 (liters) 
and 6MWTD (meters) during follow-up 1.
Supplementary Figure  S5 - Correlation between DLCO 
(mL min-1 mmHg-1) and 6MWTD (meters) during follow-up 1.
